Loading clinical trials...
Loading clinical trials...
A Phase 1, Safety, Tolerability, and Distribution Study of a Microdose of Radiolabeled BIIB067 Co-administered With BIIB067 to Healthy Adults
Conditions
Interventions
Tofersen
99mTc-MAG3-BIIB067
Locations
2
United States
Research Site
Boston, Massachusetts, United States
Research Site
New York, New York, United States
Start Date
December 20, 2018
Primary Completion Date
June 10, 2021
Completion Date
July 10, 2021
Last Updated
June 22, 2023
NCT07310264
NCT06342713
NCT07472361
NCT06823947
NCT06649110
NCT07240675
Lead Sponsor
Biogen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions